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Introduction
The prevalence of asthma, allergic rhinitis and atopic der-
matitis (AD) has dramatically increased over the past
decades. These atopy-related diseases are the most
common chronic disorders in childhood in Western soci-
eties. Several epidemiological studies have evaluated envi-
ronmental risk factors that may explain the steady increase
of allergic disease. (Note: in this article, allergic dis-
eases/atopic disorders include asthma, allergic rhinitis and
AD. Atopy-associated phenotypes/traits include, in addi-
tion, allergic sensitization, elevated total serum IgE and
eosinophilia.) There is growing evidence that contact to
bacterial antigens (such as endotoxin) and viral infections
in early childhood is protective with regard to development
of allergic disease in later life [1–6]. Although changes in
lifestyle significantly contribute to disease expression, heri-
tability has been shown to play a major role in the patho-
genesis of allergic disease.
Multiple twin and family analyses strongly imply a genetic
basis for atopy-related traits (for a review, see [7]). A
recent study of 11,688 Danish twin pairs (comparing iden-
tical and non-identical twin pairs) suggested that 73% of
asthma susceptibility is due to genetic factors [8].
However, atopy-associated phenotypes, including asthma,
do not appear to follow any Mendelian inheritance pattern,
which is characteristic for complex genetic (multifactorial)
traits. The dissection of these traits is hampered by pheno-
copy, incomplete penetrance, and genetic heterogeneity
[9]. The complexity of the genetics of asthma and other
atopy-associated phenotypes is reflected by an increas-
ingly large number of chromosomal regions showing
(weak to moderate as defined in [9]) evidence for linkage,
as well as various genetic variations in multiple candidate
genes that are associated with asthma and associated
phenotypes.
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Methodology in genetic studies of complex
traits
Microsatellite marker analysis
The majority of studies on genetics of complex traits to
date have been based on microsatellite marker (synonym,
short tandem repeat polymorphisms [STRP]) analyses.
These genetic markers (whose biological function is as yet
unknown) typically contain a variable number of tandem
repeats of dinucleotide, trinucleotide or tetranucleotide
DNA sequences (e.g. the tetranucleotide [TATA]n). The
high degree of polymorphism results in great variation
between individuals. Short tandem repeat polymorphisms
of known location are found densely spaced throughout
the genome and are used for genome-wide searches as
well as for the analysis of candidate gene regions.
Study designs in analyses of complex genetic traits
Most studies on the genetics of asthma are based on allele
sharing methods, transmission disequilibrium test (TDT)
analysis, or tests for associations. The allele sharing
methods approach involves testing how often a genetic
marker (or a chromosomal region) is shared by affected
pedigree members. If allele sharing occurs significantly
more often than expected by chance, linkage of the particu-
lar marker and disease can be assumed, indicating that the
chromosomal region containing the genetic marker also
contains a gene that contributes to disease expression.
The TDT approach is based on genotype analysis of
affected subjects (no siblings are required) and their
parents. The TDT tests whether genetic marker alleles
from heterozygous parents are transmitted as frequently
as expected by chance (by random, each parental allele is
transmitted with a chance of 50%). Overtransmission of a
particular marker allele indicates linkage of this allele with
the respective ‘disease’ allele.
Association studies are usually applied once polymor-
phisms in candidate genes for asthma/atopy have been
identified.
Linkage and candidate gene studies in
asthma and atopy
Linkage studies
Results from linkage studies (genome-wide searches and
candidate gene region analyses) are summarized in Sup-
plementary Tables 1 and 2 (see also [10–13]). Multiple
chromosomal regions were related to asthma and atopy.
Few regions, however, have shown evidence for linkage in
more than one population (Supplementary Table 2), which
may be due to racial differences, to different definition of
phenotypes, or (most probably) to insufficient numbers of
affected sib-pairs in different study populations. The first
successful attempts have been made to pool data from
genetic studies of asthma and atopy in order to analyze
major candidate gene regions [14,15].
Despite the high degree of inconsistent findings, it is
intriguing that chromosomal regions linked to asthma have
also shown evidence for linkage to other inflammatory and
autoimmune diseases (such as psoriasis, inflammatory
bowel disease, type I diabetes and multiple sclerosis).
Becker et al. noted that susceptibility genes for various
autoimmune and inflammatory diseases (including asthma)
appear to cluster in 18 distinct chromosomal regions,
implying common genetic elements in inflammatory dis-
orders [16]. This speculation is further supported by two
recent genome-wide searches for AD susceptibility genes.
Regions linked to AD (Supplementary Table 1) have also
been linked to psoriasis in other studies [17,18], suggest-
ing that common genetic elements are involved in dermal
inflammatory disorders.
Candidate gene studies
Multiple genes are involved in the allergic inflammation
(shown in Supplementary Figure 1). Multiple single
nucleotide polymorphisms (SNPs) in candidate genes for
asthma and atopy have been identified, and they are pre-
sented in Supplementary Table 3. The (often conflicting)
results have to be interpreted with caution, since multiple
genotypes are commonly tested for a large number of
atopy-related (sub)phenotypes (using various statistical
approaches) in often considerably small sample sizes.
Therefore, type 1 errors (false-positive results) are likely to
occur. In addition, publication favors positive results and,
therefore, many negative studies have not been published.
Functional studies
Many SNPs listed in Supplementary Table 3 have been
tested for functional differences in vitro. However, when
several (potentially) functional SNPs are expressed in one
(regulatory region of a) gene (e.g. IL-4Rα, IL-13, beta-2
adrenergic receptor [β2AR]), they are likely to interact. The
individual analysis of SNPs may therefore not reflect in
vivo gene function, as a recent study on β2AR haplotypes
demonstrated (see ‘β2-agonists’ subsection). (Note: a
haplotype is a particular combination of alleles in a defined
region of a chromosome. It is used to describe combina-
tions of polymorphisms in a gene/chromosomal area.) In
vitro differences in gene expression or function due to
SNPs therefore have to be interpreted with caution when
several other polymorphisms within the same gene may
also alter functionality in vitro and in vivo. This notion may
explain some of the controversial findings with regard to
associations of individual SNPs in polymorphic genes (e.g.
IL-4Rα).
The importance of haplotype analysis is further supported
by the following studies. Seven SNPs in the IL-13 gene
have been shown to be tightly linked [19], and therefore
association studies of individual SNPs with the assumption
of independent inheritance cannot easily be performed.
Also, several SNPs within the IL-4Rα gene have been iden-Page 3 of 15
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tified (see Supplementary Table 3). An association of two
individual SNPs (S503P and Q576R) with decreased
serum IgE levels was observed in a Caucasian population;
however, most significant results with regard to low IgE
levels were seen when both SNPs occurred together [20].
Similarly, Ober et al. performed TDT analysis for IL-4Rα
SNPs and haplotypes in four populations. Again, the
strongest evidence for linkage to asthma and/or atopy was
observed with two-locus haplotype analysis [21].
Gene–gene interactions
Gene–gene interactions also have to be taken into consid-
eration; for example, when both the genes encoding pro-
inflammatory cytokines (i.e. IL-13) as well as their
receptors (IL-4Rα) and/or genes involved in signal trans-
duction (STAT6) bear polymorphisms associated with
disease. The first studies have demonstrated the feasibility
and importance of gene–gene interaction in atopy [22].
Gene–environment interactions
Pharmacogenetics
A marked disparity in treatment response to pharma-
cotherapy is observed in asthma (as well as in many other
diseases). Variations in genes encoding proteins that
interact with specific drugs or drug metabolism are likely
to contribute to variability in treatment response. The best
examined gene with regard to pharmacogenetics is the
gene encoding the enzyme cytochrome p450, for which
various alterations that affect the metabolism of multiple
drugs have been described. Gene chips for the determina-
tion of p450 alleles are commercially available in Sweden
and North America (reviewed in [23]).
Pharmacotherapy of asthma and atopy comprises β-ago-
nists, corticosteroids, anti-histamines (H1-receptor antag-
onists) and leukotriene (receptor) antagonists. The
following pharmacogenetic studies have been performed.
β2-agonists
β2-agonists are the most widely used drugs in the treat-
ment of asthma. They exert their primary effect on the
β2AR of bronchial smooth muscle. The gene encoding the
β2AR maps to chromosome 5q33 and is the best exam-
ined candidate gene with regard to pharmacogenetic
studies in asthma. Several SNPs within the coding region
and the promoter of the β2AR have been identified (sum-
marized in [24]; see also Supplementary Table 3). Three
mutations that result in amino acid changes of the mature
protein (Gly16Arg, Gln27Glu, and Thr164Ile) lead to func-
tional changes. The Gly16 variant was shown to undergo
enhanced agonist-promoted downregulation in vitro. Inter-
estingly, a strong association of the Gly16 polymorphism
and nocturnal asthma could be demonstrated [25], which
may explain the β2AR downregulation observed in noctur-
nal asthmatics but not in non-nocturnal asthmatics [26].
Conflicting results have been reported with regard to
β2AR SNPs and response to β2-agonists (summarized in
Supplementary Table 3). A large multicenter study demon-
strated that patients homozygous for the Arg16 variant
developed a decline in peak flow when using albuterol on
a regular basis [27]. However, a recent haplotype analysis
[24] indicated that β2AR SNPs are not independently
transmitted and should presumably not be tested sepa-
rately for associations with asthma or differences in drug
response. Drysdale et al. demonstrated that only a limited
number of β2AR haplotypes can be found in several ethnic
groups, far less than theoretically possible. Furthermore,
response to β2-agonists in asthmatic individuals signifi-
cantly related to distinct haplotypes but not to individual
SNPs. Consistent with the in vivo data, transfection of
cells with the β2AR haplotype associated with a better
response to β2-agonists resulted in significant greater
mRNA levels and β2AR receptor density compared with
the lower response haplotype [24].
Corticosteroids
Despite the large variability in the steroid response of
asthmatic individuals, genetic variations in the glucocorti-
coid receptor gene have as yet to be identified in steroid-
dependent asthmatics.
Anti-histamines
No functionally relevant polymorphism has been found in
the H1-histamine receptor gene [23]. However, a func-
tional mutation in the gene encoding the histamine-
degrading enzyme N-methyltransferase has been related
to asthma [28].
Leukotriene antagonists
Leukotrienes (LTC4, LTD4, LTE4) contribute to airway
inflammation and bronchoconstriction in asthmatic individ-
uals. 5-lipoxygenase (5-LO) (gene symbol, ALOX5; chro-
mosome, 10q11.2) is a crucial enzyme in the synthesis of
leukotrienes. The activity of 5-LO determines, at least in
part, the concentration of leukotrienes in the airways.
Drazen  et al. [29] described frequently occurring muta-
tions in the 5-LO promoter (three to six tandem repeats of
an Sp-1 binding site, with the wild-type allele having five
copies) that result in a decreased transcriptional activity.
In patients with asthma, only those individuals that
expressed the wild-type 5-LO promoter responded well to
therapy with a 5-LO inhibitor (ABT-761, the drug was
never marketed), whereas individuals with both 5-LO pro-
moter alleles mutated showed no significant improvement
of lung function when treated. It has not yet been exam-
ined whether these mutations also affect the responses of
asthma patients to leukotriene receptor antagonists (e.g.
montelukast, zafirlukast).
Sanak et al. described a polymorphism within the leuko-
triene C4 synthase promoter that resulted in higher risk of
Available online http://respiratory-research.com/content/3/1/7aspirin-induced asthma. This genetic variant may also alter
response to treatment with drugs directed against leuko-
trienes [30].
In conclusion, the studies by Drazen et al. [29] and Drys-
dale et al. [24] in particular indicate that genetic testing
may help to predict drug response and may eventually be
used to optimize individual pharmacotherapy.
Genetics of host-defence
Apart from pharmacogenetic studies, the analysis of
gene–environment interactions to date is hypothesis
driven. The difficulties in quantifying and characterizing
environmental risk factors for atopy (including onset and
length of period of exposure) make these studies a chal-
lenge. Very high numbers of affected and unaffected sub-
jects carefully characterized (longitudinally) for both the
environmental setting and disease expression may be
required to test for interactions between genetic variants
and non-genetic influences.
However, recent genetic studies support the ‘hygiene
hypothesis’, which postulates that atopy may be the result of
a misdirected immune response in the absence of infection.
First, resistance to Schistosoma mansoni [31] and Plas-
modium falciparum blood levels [32] (two independent
studies) were linked to chromosome 5q31-33, a region
(containing the IL-4 cytokine gene cluster) that has shown
strong evidence for linkage to atopy-associated traits. Fur-
thermore, a major locus closely linked to the interferon-γ
receptor gene appears to control the switch from a T
helper 2 to a T helper 1 cytokine profile during S. mansoni
infection [33,34].
Second, SNPs within the FcεRI-β gene have been related
to increased total serum IgE levels in heavily parasitized
Australian aborigines, indicating a protective role in para-
sitic infection [35]. These SNPs have also been related to
asthma, bronchial hyperresponsiveness, AD and atopy
(see Supplementary Table 3). FcεRI-β maps to 11q13, a
region that showed evidence for linkage to asthma and
associated traits in multiple studies (Supplementary
Table 3).
Finally, a polymorphism in the β2AR encoding gene
(Arg16) that has been related to asthma (see Supplemen-
tary Table 3) was also associated with higher levels of par-
asitic infection [36].
Ethnic differences in ‘host defense’ and
‘atopy’ genes
Evolutionary pressure with regard to infectious agents has
differed significantly between continents. Significant
ethnic differences in genes involved in immune defense
mechanisms have been reported and may be based on
differences in natural selection over the past centuries.
Racial differences in genes involved in both host defense
and allergic inflammation can best be demonstrated for
CC chemokines and their receptors. CC chemokines have
been shown to be crucial mediators of the allergic inflam-
mation due to their potent chemoattractant properties for
eosinophils, basophils and T cells [37]. Observations with
regard to ethnic differences are as follows.
Evidence for linkage to chromosome 17q11.2 (a region
that contains the CC chemokine gene cluster) has been
reported in African Americans [38] but not in any Cau-
casian population (Supplementary Table 1).
A 32 base pair deletion in the CC chemokine receptor
CCR5 renders individuals resistant to infection with
macrophage-tropic HIV strains. This mutation is found in
>10% of Caucasians, whereas it cannot be found in
African populations [39]. A reduced risk of asthma was
reported for carriers of the CCR5 deletion [40]. However,
this could not be confirmed by Mitchell et al. [41].
In contrast to Caucasian individuals, the Duffy Antigen/
Receptor for Chemokines is not expressed on red blood
cells in the vast majority of African people (a point muta-
tion in the Duffy promoter abolishes erythrocyte gene
expression). This confers an evolutionary advantage since
Duffy-negative erythrocytes are resistant to infection by
Plasmodium vivax, which is endemic in most of Africa.
Duffy has been shown to bind with high affinity to
chemokines of both the CXC and CC classes, and is
believed to function as a clearance receptor for
chemokines (reviewed in [42]). It can therefore be hypoth-
esized that higher or longer exposure to chemokines due
to the absence of Duffy on erythrocytes might contribute
to asthma pathogenesis in subjects of African descent.
A functional mutation in the proximal promoter of the CC
chemokine RANTES was significantly more frequent
among individuals of African descent compared with Cau-
casian subjects [43]. This mutation was associated with
AD [43], asthma and atopy [44].
The 3′ untranslated region of eotaxin has shown a much
higher degree of polymorphism in African American and
Afro-Caribbean individuals than in Caucasians. Polymor-
phic alleles were in linkage disequilibrium with asthma in
both African American and Afro-Caribbean families, but
not in Caucasian families [45]
Ethnic differences have also been described for various
other genes involved in the allergic inflammation (e.g.
IL-4Rα [21], β2AR [24]). We can therefore speculate that
inconsistent findings in the genetic studies of asthma and
atopy summarized in this article may partly be explained by
ethnic differences in nature and frequencies of genetic
Respiratory Research    Vol 3 No 1 Sengler et al.
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speculate that ethnic differences in inflammatory genes (in
addition to environmental factors) may also underlie the
significant worldwide differences in the prevalence of
asthma, allergic rhinitis, and AD [46].
Conclusion
Asthma and atopy are complex, multifactorial disorders.
Major strides have been made in identifying chromosomal
regions and candidate genes linked to asthma. However,
the significant increase in the prevalence of atopy-related
disorders over the past decades cannot be explained by
changes in gene frequencies. It is rather probable that
various pre-existing genetic factors interacting with a dra-
matically changing environment (decline of infectious dis-
eases, change in diet, immunizations, and others) have
rendered a large percentage of the population susceptible
to asthma and atopy. Genetic variations that evolved to
improve resistance to infections may very probably be mis-
directed to promote allergic inflammation in the absence
of infection in Western societies. Redundancies in host
defense mechanisms may explain the large number of
chromosomal regions as well as a steadily growing
number of genetic variants related to atopy. Inconsistent
findings summarized in this article may be explained by
ethnic differences in host defense genes, but also by limi-
tations to taking gene–gene as well as gene–environment
interactions into account. Large prospective, multicenter
studies, in addition to retrospective collaborations as
described previously [14], may help to better understand
genetic and environmental risk factors for atopy.
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Supplementary Figure 1
Simplified cartoon of the allergic inflammation showing the mechanisms and molecules involved starting from antigen-presentation to organ-specific
allergic reactions. Outlined are most candidate genes for atopy-associated phenotypes that have been analyzed to date (superscript numbers refer
to Supplementary Table 3). APC, antigen presenting cell; AG, antigen; B7, costimulatory molecule B7; CC16, Clara cell protein 16; CCR5, CC
chemokine receptor 5; CD, cluster of differentiation; CD40L, CD40 ligand; ECP, eosinophilic cationic protein; FcεR1-β, Fc epsilon receptor 1 beta
(IgE receptor); GSTP1, glutathione-S-transferase 1; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; IRF-1, interferon regulatory factor
1; LT, leukotriene; LTC4, leukotriene C4 synthase; MBP, major basic protein; NO, nitric oxide; PAF, platelet activating factor; RANTES, regulated
on activation, normal T cell expressed and secreted; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; Th, T helper cell.R
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Supplementary Table 1
Results of genome-wide searches (asthma and associated traits)
Study
Hizawa Daniels  Ober  Ober  Wjst  Yokouchi  Lee Cookson
CSGA 1  et al.  et al.  et al.  et al.  et al.  et al. EGEA et al.  et al. 
(1997) (1998) (1996) (1998) (2000)† (1999) (2000) (2000) (2000) (2001)
C C C C  (German/ C C C C
Population AA C H AA C (Australian) (Hutterites) (Hutterites) Swedish) Japanese (French) (German) (British)
Individuals (n) 117‡ 215‡ 48‡ 281 299 364 371/292 693 415 196 493 839
Sib-pairs (n) ns ns ns ns ns 172 ns ns 156 65 ns 199 213
1q21 AD*
1p31 Asthma *
2pter Asthma*, IgE**
BHR*, RAST**
2q22-33 Asthma* IgE*
3q21 AD***
4q35 BHR**, atopy* Asthma**
5p13-15 Asthma** BHR 
(D5S1470)
5q23-33 IgE* BHR** BHR Asthma***
(D5S1462)
6p21.3-23 IgE* Eos*** Asthma*, IgE*
RAST*
7p IgE*, BHR** 
(D7S2250, D7S484)
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Supplementary Table 1 Continued
Study
Hizawa Daniels  Ober  Ober  Wjst  Yokouchi  Lee Cookson
CSGA 1  et al.  et al.  et al.  et al.  et al.  et al. EGEA et al.  et al. 
(1997) (1998) (1996) (1998) (2000)† (1999) (2000) (2000) (2000) (2001)
C C C C  (German/ C C C C
Population AA C H AA C (Australian) (Hutterites) (Hutterites) Swedish) Japanese (French) (German) (British)
8p23.3 IgE* Asthma
(D8S1136)
9 (DS1784) Asthma*, IgE*
RAST*
11p13-15 Asthma * IgE*
11q13 IgE**, ST*** IgE*
12q13-24.2 Asthma* BHR* Asthma* Eos**
13q11-32.2 Asthma* IgE* Atopy** Asthma** Eos*
14q11.2-13 Asthma*
14q32 BHR
(gata193a07)
16q-tel IgE**
16q23-24 IgE** ST (D16S539)
17p11.1-q11.2 Asthma*
17q12-21 Asthma/ST*
17q25 AD**
19q13 Asthma* Asthma* BHR BHR*
(D19S900)
20p Asthma**
21q21 Asthma*
AA, African American; AD, Atopic dermatitis; BHR, bronchial hyperresponsiveness; C, Caucasian; eos, eosinophil count; H, Hispanic; ns, not specified; RAST, radio allergo sorbent test; ST,
positive skin test. * P ≤ 0.01, ** P ≤ 0.001, *** P ≤ 0.0001. † Statistical significance (P ≤ 0.05) in both tests, likelihood ratio χ2 test and transmission disequilibrium test. ‡ Only affected
individuals, neither number of all individuals nor number of sib-pairs specified [17,18,38,S1–S7].Respiratory Research    Vol 3 No 1 Sengler et al.
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Supplementary Table 2
Chromosomal regions showing evidence for linkage to asthma and related phenotypes
Chromosomal region Phenotype (linkage) Population Reference
5q23-33 Total IgE Dutch, Amish, Caucasian (UK) [S8–S10]
Total IgE, specific IgE, eosinophil count Australian [S11]
Specific IgE African American [S12]*
Atopic dermatitis Caucasian (UK), German/Swedish [S13,S14]
Asthma/atopy Japanese [S6,S15]*
Eosinophil count Caucasian (US) [S16]
Hypereosinophilia Caucasian (US) [S17]
Bronchial hyperresponsiveness Dutch, Hutterites [S3,S18]*
6p21-23 Specific IgE Caucasian (US) [S1*,S19]
Asthma, IgE German/Swedish [S5]*
Allergic asthma Colombian [S20]
Eosinophil count Caucasian (Australian) [S2]*
11q13 IgE Caucasian (UK) [S21,S22]
IgE, positive skin test Caucasian (Australian) [S2]*
Specific IgE Caucasian (Australian), African American [S11,S12]
Bronchial hyperresponsiveness, log IgE Caucasian (UK) [S10]
Bronchial hyperresponsiveness Caucasian [S23]
Atopy Japanese [S24]
Asthma, atopy Caucasian [S25]
Atopic dermatitis German [S26]
12q14-24 Asthma German/Swedish Caucasian (US) [38,S27]*
Caucasian (UK) [S28]
Asthma, atopy Afro-Caribbean [S29]
Total IgE, asthma Afro-Caribbean, Amish [S30]
Total IgE German [S31]
Bronchial hyperresponsiveness Hutterites [S3]*
Eosinophil count French [S7]*
13q11-32 Atopic dermatitis German/Swedish [S14]
Specific IgE Caucasian (UK) [S1]*
Atopy Caucasian (Australian) [S2]*
Eosinophil count French [S7]*
Asthma Caucasian (US), Japanese [38*,S6*]
Atopic asthma Japanese [S32]
* Genome-wide searches.Available online http://respiratory-research.com/content/3/1/7
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Supplementary Table 3
Polymorphisms/mutations in candidate genes for asthma and related phenotypes
Chromosomal Single  nucleotide  Phenotype  Functional 
location Number* Molecule polymorphism/mutation† related Population (in vitro) Reference
1p32 1 Histamine-N- C314T (Thr105Ile) Asthma Caucasian Yes [28]
methyl-transferase
2q33-34 2 CD28 T19int3C None Caucasian [S33]
CTLA-4 A49G None Caucasian [S33]
C-318T None Caucasian
3p21 3 CCR5 CC5-∆32 Asthma Caucasian Yes [40]
No Association British/Australian [41]
5q31-34 4 IL-4 C-590T Total IgE Japanese Yes [S34]
(= C-589T) Total IgE American [S35]
Specific IgE, wheeze Australian [S36]
FEV1 Caucasian [S37]
Atopic dermatitis Japanese [S38]
None Caucasian [S39]
C+33T Total IgE Japanese [S40]
5 IL-5 None Australian [S41]
6 IL-13 C-1055T Allergic asthma Dutch [S42]
C-1112T Total IgE American/German [19]
A-1512C
C1923T
G2525A
C2580A
C2749T
Arg130Gln
G4257A High IgE, atopic dermatitis German [S43]
Gln110Arg Atopic and intrinsic British/Japanese [S44]
asthma
7 β2-AR G-1023A
C-709A
G-654A
C-468G
C-406T
T-367C Drug response Caucasian/African American Yes [24]
T-47C (Haplotype studies) Asian/Hispanic-Latino
T-20C
G46A (= Gly16Arg)
C79G (= Gln27Glu)
G252A
C491T (= Thr164Ile)
C523A
Gly16Arg Drug response American Yes [27]
FEV1 and FVC Hutterites [S45]
Asthma severity Not specified [S46]
Gly16Arg Nocturnal asthma American [25]
Steroid-dependent asthma American [S47]
None German [S48]
Drug response Not specified [S49]
Gln27Glu Drug response American Yes [27]
Drug response Not specified [S49]
None German [S48]
Total IgE Caucasian [S50]
FEV1 British [S51]
8 IRF-1 –300 G/T None Japanese [S52]
4396 A/G None
6355 G/A None
9 CD14 –159 C → T Total IgE Caucasian [S53]
None Hispanic [S53]
Total IgE British  [S54]
None Japanese [S54]
5q35 10 LTC4 synthase –444 C Aspirin-induced asthma Caucasian Yes [30]
None American No [S55]
identical
identical


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Supplementary Table 3 Continued
Chromosomal Single  nucleotide  Phenotype  Functional 
location Number* Molecule polymorphism/mutation† related Population (in vitro) Reference
6p21 11 HLA-II Specific IgE Multiple [S56]
TNF –308 TNF2 BHR Caucasian [S57]
LT-α LT alpha NcoI*1/ Asthma British [S58]
TNF-308*2 haplotype
–308 TNF1 Asthma Australian [S59]
LT-alpha*2 Asthma
6p21-12 24 PAF-acetyl-hydrolase Ile198Thr Atopic Asthma/ German/British Yes [S60]
total IgE
Ala379Val Asthma/specific IgE Yes
Arg92His None Yes
10 12 5-LO (promoter) (GGGCGG)n = 3–6 Drug Response Not specified Yes [29]
11q12-13 14 CC16 A38G Asthma Australian [S61]
None British/Japanese [S62]
15 FcεR1-β lle181Leu Atopy British No [S63]
Japanese [S64]
Leu181/Leu183 Atopy, BHR British/Australian No [S65]
None Australian [S51]
E237G (= Gly237Glu) Atopy Australian No [S66]
None Japanese [S67]
RsaI_in2*B Asthma Australian [S68]
RsaI_ex7 (+ RsaI_in2*B) Total IgE, atopic  Not specified [S69]
dermatitis, asthma
–109C/T Total IgE Japanese [S70]
13 GSTP1 Ile105Val IgE/Skin Test/FEV1 Caucasian [S71]
12q13 17 STAT6 G2964A Asthma Japanese [S72]
12q14 16 IFN-γ None Australian/Venezuelan [S73]
12q24 18 NO-synthase 1 (AAT)n ≥ 12 Exhaled NO Mixed [S74]
14p11 19 TCR VA8.1(*)2 Specific IgE Caucasian [S75]
20 Mast cell chymase MCC BstXI Eczema Japanese [S76]
Total IgE Not specified [S77]
None Japanese [S78]
None Italian [S79]
Atopic dermatitis Japanese [S80]
With high IgE
16p12-p11 21 IL-4Rα Q576R (= Arg551Gln) Atopy, high IgE American Yes [S81]
Asthma severity (FEV1) American [S82]
None Italian [S83]
Atopic dermatitis Japanese [S84]
Low IgE German Yes [20]
S503P (= 478Pro) Low IgE [20]
E400A None
C431R None
Ile50Val IgE/atopic asthma Japanese Yes [S85]
None Japanese [S86]
Ile50Val
Ser727Ala
Glu375Ala
Cys406Arg Atopy/asthma Hutterites/Caucasian [21]
Ser411Leu (Haplotype studies) African American/Hispanic
Ser761Pro
Ser478Pro
Gln551Arg
17q11-q12 22 RANTES G-401A Atopic dermatitis Caucasian Yes [43]
G-403A Asthma, atopy Caucasian [44]
Xq 23 IL-13Rα1 A1398G Total IgE British [S44]
Divergent positions of identical mutations are due to different database accession numbers used for reference. * Numbers refer to molecules in
Supplementary Figure 1. † Nomenclature as in references. β2-AR, β2 adrenergic receptor; BHR, bronchial hyperresponsiveness; CC16, Clara cell
protein 16; CCR5, CC chemokine receptor 5; CD, cluster of differentiation; FcεR1-β, Fc epsilon receptor 1 beta (IgE receptor); FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 s; GSTP1, glutathione-S-transferase 1; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin;
IL-4/13 R, interleukin 4/13 receptor; IRF-1, interferon regulatory factor 1; 5-LO, 5-lipoxygenase; LT, leukotriene; LT-α, lymphotoxin α; LTC4,
leukotriene C4 synthase; NO, nitric oxide; PAF, platelet activating factor; RANTES, regulated on activation, normal T cell expressed and secreted;
STAT6, signal transducer and activator of transcription 6; TCR, T-cell receptor; TNF, tumor necrosis factor.
identical

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